Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference

Stereotaxis Inc. (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular interventions, has announced its participation in the Piper Sandler 37th Annual Healthcare Conference taking place on December 3, 2025. David Fischel, the company’s Chairman and CEO, will engage in a fireside chat at 9:00 a.m. Eastern Standard Time and is scheduled for one-on-one meetings with investors later that day. Mr. Fischel expressed enthusiasm about the company’s growth trajectory, highlighting the achievement of significant regulatory milestones and early commercial success.

Founded with a mission to advance surgical robotics, Stereotaxis develops innovative systems, instruments, and information solutions for the interventional laboratory, enhancing patient care through robotic precision and safety. Their technology has been utilized to treat over 150,000 patients worldwide, showcasing its reach and impact on healthcare.

In addition to the conference details, the company's press release includes cautionary forward-looking statements regarding its future prospects. These statements imply potential risks and uncertainties that could affect actual results, such as the acceptance of their products, regulatory approval timelines, and broader economic conditions. The press release underscores that Stereotaxis does not commit to revising its forward-looking statements in response to changes that may occur after the announcement date.

Stereotaxis invites inquiries through its executive team, including David Fischel and CFO Kimberly Peery, emphasizing their willingness to engage with investors and stakeholders regarding future developments. For further information about Stereotaxis and its offerings, interested parties can visit their official website.

As Stereotaxis (NYSE: STXS) gears up to participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, it presents a unique opportunity for investors to consider the future potential of the company in the rapidly advancing field of surgical robotics. With David Fischel, the Chairman and CEO, expected to engage in a fireside chat and be available for one-on-one meetings, it's a pivotal moment for the firm to communicate its growth strategy and recent successes in obtaining critical regulatory approvals.

Stereotaxis has positioned itself as a leader in minimally invasive endovascular intervention, having treated over 150,000 patients globally with its innovative robotic systems. The emphasis on technology that enhances patient care, safety, and operational efficiency positions the company well against competitors. As healthcare continues to shift towards minimally invasive procedures, Stereotaxis stands to benefit significantly from this trend, especially as hospitals seek to improve patient outcomes and reduce recovery times.

However, potential investors should remain cognizant of the inherent risks associated with such forward-looking statements and the uncertainties surrounding healthcare innovations. Factors such as market acceptance, regulatory hurdles, and economic conditions can directly impact revenue recognition and overall company performance. The upcoming conference will be crucial for Stereotaxis, as it will provide insights into how the company plans to navigate these challenges while capitalizing on its technological advancements.

In light of these dynamics, investors should approach Stereotaxis with a balanced perspective. Monitoring management's commentary at the conference and any subsequent developments will be essential in assessing the company's trajectory, making it a watchlist candidate for those looking to invest in the healthcare technology sector. As always, conducting thorough due diligence and considering market conditions will be key to navigating investment decisions in this field.